The additive effects of the active component of grapefruit juice (naringenin) and antiarrhythmic drugs on HERG inhibition

Cardiology

Volumn 110, Issue 3, 2008, Pages 145-152

  Lin, Congrong ^a   Ke, Xiaogang ^a   Ranade, Vasant ^a   Somberg, John ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiarrhythmic agents; Arrhythmia; Ion channels; Torsade de pointes

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; AZIMILIDE; DOFETILIDE; NARINGENIN; POTASSIUM CHANNEL HERG; QUINIDINE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; GRAPEFRUIT JUICE; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; VOLTAGE CLAMP;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; BEVERAGES; CITRUS PARADISI; DELAYED RECTIFIER POTASSIUM CHANNELS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; FLAVANONES; FOOD-DRUG INTERACTIONS; OOCYTES; PATCH-CLAMP TECHNIQUES; XENOPUS;

EID: 41549123712     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000111923     Document Type: Article

References (33)

1. Timberlake CF, Henry BS: Plant pigments as natural food colours. Endeavour 1986;10:31-36.
2. Middleton E Jr, Kandaswami C, Theoharides TC: The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 2000;52:673-751.
3. Scalbert A, Williamson G: Dietary intake and bioavailability of polyphenols. J Nutr 2000;130(8S suppl):2073S-2085S.
4. Rousseff RL, Martin SF, Youtsey CO: Quantitative survey of narirutin, naringin, hesperidin and neohesperidin in citrus. J Agric Food Chem 1987;35:1027-1030.
5. Beecher GR: Overview of dietary flavonoids: nomenclature, occurrence and intake. J Nutr 2003;133:3248S-3254S.
6. Graf BA, Milbury PE, Blumberg JB: Flavonols, flavones, flavanones, and human health: epidemiological evidence. J Med Food 2005;8:281-290.
7. Engler MB, Engler MM: The emerging role of flavonoid-rich cocoa and chocolate in cardiovascular health and disease. Nutr Rev 2006;64:109-118.
8. Zitron E, Scholz E, Owen RW, Luck S, Kiesecker C, Thomas D, Kathofer S, Niroomand F, Kiehn J, Kreye VA, Katus HA, Schoels W, Karle CA: QTc prolongation by grapefruit juice and its potential pharmacological basis: HERG channel blockade by flavonoids. Circulation 2005;111:835-838.
9. Scholz EP, Zitron E, Kiesecker C, Luck S, Thomas D, Kathofer S, Kreye VA, Katus HA, Kiehn J, Schoels W, Karle CA: Inhibition of cardiac HERG channels by grapefruit flavonoid naringenin: implications for the influence of dietary compounds on cardiac repolarisation. Naunyn Schmiedebergs Arch Pharmacol 2005;371:516-525.
10. Sanguinetti MC, Jiang C, Curran ME, Keating MT: A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995;81:299-307.
11. Trudeau MC, Warmke JW, Ganetzky B, Robertson GA: HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 1995;269:92-95.
12. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG: Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003;58:32-45.
13. Nair LA, Grant AO: Emerging class III antiarrhythmic agents: mechanism of action and proarrhythmic potential. Cardiovasc Drugs Ther 1997;11:149-167.
14. Roden DM: Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-1022.
15. Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, Escande D, Franz M, Malik M, Moss A, Shah R: The potential for QT prolongation and proarrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 2000;47:219-233.
16. Hohnloser SH: Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management. Am J Cardiol 1997;80(8A):82G-89G.
17. Camm AJ, Janse MJ, Roden DM, Rosen MR, Cinca J, Cobbe SM: Congenital and acquired long QT syndrome. Eur Heart J 2000;21:1232-1237.
18. Phillips L, Grasela TH, Agnew JR, Ludwig EA, Thompson GA: A population pharmacokinetic-pharmacodynamic analysis and model validation of azimilide. Clin Pharmacol Ther 2001;70:370-383.
19. Kowey PR, Marinchak RA, Rials SJ, Bharucha D: Pharmacologic and pharmacokinetic profile of class III antiarrhythmic drugs. Am J Cardiol 1997;80(8A):16G-23G.
20. Madeja M, Musshoff U, Speckmann EJ: Follicular tissues reduce drug effects on ion channels in oocytes of Xenopus laevis. Eur J Neurosci 1997;9:599-604.
21. Kawaii S, Tomono Y, Katase E, Ogawa K, Yano M: Quantitation of flavonoid constituents in citrus fruits. J Agric Food Chem 1999;47:3565-3571.
22. Mouly P, Gaydou EM, Auffray A: Simultaneous separation of flavanone glycosides and polymethoxylated flavones in citrus juices using liquid chromatography. J Chromatogr A 1998;800:171-179.
23. Erlund I, Meririnne E, Alfthan G, Aro A: Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice. J Nutr 2001;131:235-241.
24. Roden DM, Woosley RL, Primm RK: Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J 1986;111:1088-1093.
25. Lin C, Cvetanovic I, Ke X, Ranade V, Somberg J: A mechanism for the potential proarrhythmic effect of acidosis, bradycardia, and hypokalemia on the blockade of human ether-a-go-go-related gene (HERG) channels. Am J Ther 2005;12:328-336.
26. Lin C, Ke X, Cvetanovic I, Ranade V, Somberg J: The effect of high extracellular potassium on IKr inhibition by anti-arrhythmic agents. Cardiology 2006;108:18-27.
27. Lin C, Ke X, Cvetanovic I, Ranade V, Somberg J: The influence of extracellular acidosis on the effect of IKr blockers. J Cardiovasc Pharmacol Ther 2005;10:67-76.
28. Napolitano C, Schwartz PJ, Brown AM, Ronchetti E, Bianchi L, Pinnavaia A, Acquaro G, Priori SG: Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol 2000;11:691-696.
29. Lohezic-Le Devehat F, Marigny K, Doucet M, Javaudin L: Grapefruit juice and drugs: a hazardous combination? Therapie 2002;57:432-445.
30. Fuhr U: Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance. Drug Saf 1998;18:251-272.
31. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W, Watkins PB: Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997;99:2545-2553.
32. Libersa CC, Brique SA, Motte KB, Caron JF, Guedon-Moreau LM, Humbert L, Vincent A, Devos P, Lhermitte MA: Dramatic inhibition of amiodarone metabolism induced by grapefruit juice. Br J Clin Pharmacol 2000;49:373-378.
33. Damkier P, Hansen LL, Brosen K: Effect of diclofenac, disulfiram, itraconazole, grape-fruit juice and erythromycin on the pharmacokinetics of quinidine. Br J Clin Pharmacol 1999;48:829-838.